Omnix Medical

About

Funding history · 5 rounds · $54.7M total

Headcount over time

Offices

Q&A

What is Omnix Medical's primary focus?

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing novel antibiotic agents to combat infections caused by drug-resistant bacteria.

When was Omnix Medical founded?

Omnix Medical was founded in 2015.

How many employees does Omnix Medical currently have?

Omnix Medical has 11-50 employees.

What is the status of Omnix Medical's lead compound, OMN6?

OMN6 is a first-in-class antimicrobial peptide (AMP) that has received Fast-Track and Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA. In June 2026, Omnix Medical announced the first patients were dosed in a Phase II trial for OMN6.

What was Omnix Medical's most recent funding round?

In October 2025, Omnix Medical completed a C Round, raising $25,000,000. The round was co-led by Harel Insurance & Finance and EIC Fund.

Which organizations provided grants to Omnix Medical in 2023?

In October 2023, Omnix Medical received a grant of $11,664,000 from the European Union.

Who are the co-founders of Omnix Medical?

The co-founders of Omnix Medical are Dr. Moshik Cohen-Kutner (Co-Founder and CEO), Dr. Niv Bachnoff (Co-Founder and CSO), and Rom Lakritz (Co-Founder and CFO/COO).

What is the mechanism of action for Omnix Medical's technology?

Omnix Medical's technology eliminates bacteria by mimicking the innate immune system of insects, using unique molecules to kill resistant bacterial strains efficiently and selectively without toxic effects.

Team · 30

Dr. Moshik Cohen-Kutner

Founder · Co-Founder And CEO

Dr. Niv Bachnoff

Founder · Co-Founder And CSO

Rom Lakritz

Founder · Co-Founder and CFO/COO

Dr. Antonius Schuh

Chairman Of The Board Of Directors

Dr. Yafit Stark

Director, Regulatory And Clinical Advisor

Tomer Goldberg

Vice President, Managing Director Harel Technology Investments at Harel Insurance & Finance

Ran Achituv

Entr'ee Capital General Partner

Helena Bond

Investment Officer Non-voting observer on behalf of the EIC Fund

Eyal Dior

Founder & Managing Partner at Tal Ventures

Anat Tsour Segal

Board Member Xenia Venture Capital

Prof. Roger D. Kornberg

Advisory

Dr. Lynn L. Silver

Microbiology Development Advisory

Prof. Yehuda Carmeli, MD

Medical Advisory

Keith A. Rodvold, Pharm.D., FCCP, FIDSA

Clinical Advisory

Keith Kaye, MD, MPH

Clinical Advisory

Lihi Elyahu

VP Operations & Human Resources

Bella Shusterman

VP Clinical Development

Shira Mandel

VP Research & Discovery

Noa Nur-Maymon

Director of Translational Research & IP Strategy

Jonathan Zazoun

Head of CMC and Non-Dilutive Funding

Tamar Shachar

VP Strategy and Drug Development

Ofra Barchad-Avitzur

Senior Director of Clinical Affairs

Shelly Maximov

Director of Preclinical Development & Regulation

Elital Chass-Maurice

Director of Clinical Operation

Orel Mayost Lev-Ari

Research Associate

Inbal Doron

Research Associate

Ori Heyman

Head of International R&D Program

Amir Ben-Dror

Project Manager

Meirav Belo

Office Manager

Deborah Mimoun

Clinical Operations Associate

Sectors & technology

Highlights

Tags